Viracta Therapeutics unveiled positive data from a Phase 2 trial showing the combination therapy of nanatinostat and valganciclovir elicited promising response rates among patients with Epstein-Barr Virus-positive relapsed or refractory peripheral T-cell lymphoma. "The substantially greater clinical efficacy of Nana-valrelative to nanatinostat monotherapy suggests that both agents in the combination regimen are contributing to its anti-tumor activity as predicted by their mechanisms of action," the study's principal investigator Hung Chang said.